Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Invested Capital (2016 - 2025)

Historic Invested Capital for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$64.7 million.

  • Ironwood Pharmaceuticals' Invested Capital rose 7923.42% to -$64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year increase of 7923.42%. This contributed to the annual value of -$301.3 million for FY2024, which is 10536.0% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Invested Capital stood at -$64.7 million for Q3 2025, which was up 7923.42% from -$108.8 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Invested Capital peaked at $722.8 million during Q4 2021, and registered a low of -$334.1 million during Q1 2025.
  • Moreover, its 5-year median value for Invested Capital was -$64.7 million (2025), whereas its average is $172.7 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Invested Capital soared by 1166783.54% in 2021 and then plummeted by 15555.24% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Invested Capital (Quarter) stood at $722.8 million in 2021, then fell by 9.74% to $652.4 million in 2022, then tumbled by 122.49% to -$146.7 million in 2023, then plummeted by 105.36% to -$301.3 million in 2024, then surged by 78.55% to -$64.7 million in 2025.
  • Its last three reported values are -$64.7 million in Q3 2025, -$108.8 million for Q2 2025, and -$334.1 million during Q1 2025.